159 related articles for article (PubMed ID: 31213414)
1. Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial.
Abdel-Rahman O
Clin Genitourin Cancer; 2019 Aug; 17(4):e837-e844. PubMed ID: 31213414
[TBL] [Abstract][Full Text] [Related]
2. Evaluating Family History Links between Breast Cancer and Prostate Cancer Among PLCO Trial Participants.
Abdel-Rahman O
Clin Breast Cancer; 2020 Aug; 20(4):300-306. PubMed ID: 32327298
[TBL] [Abstract][Full Text] [Related]
3. Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer.
Schoen RE; Razzak A; Yu KJ; Berndt SI; Firl K; Riley TL; Pinsky PF
Gastroenterology; 2015 Nov; 149(6):1438-1445.e1. PubMed ID: 26255045
[TBL] [Abstract][Full Text] [Related]
4. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M
BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304
[TBL] [Abstract][Full Text] [Related]
5. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.
Pinsky PF; Prorok PC; Yu K; Kramer BS; Black A; Gohagan JK; Crawford ED; Grubb RL; Andriole GL
Cancer; 2017 Feb; 123(4):592-599. PubMed ID: 27911486
[TBL] [Abstract][Full Text] [Related]
6. Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis.
Abdel-Rahman O
Int J Clin Oncol; 2020 May; 25(5):885-891. PubMed ID: 31919692
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.
Halpern JA; Shoag JE; Mittal S; Oromendia C; Ballman KV; Hershman DL; Wright JD; Shih YT; Nguyen PL; Hu JC
J Urol; 2017 Feb; 197(2):363-368. PubMed ID: 27569432
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer incidence and survival in relation to prostate cancer as second cancer in relatives.
Zheng G; Sundquist J; Sundquist K; Ji J
Cancer Med; 2022 May; 11(10):2117-2124. PubMed ID: 35312170
[TBL] [Abstract][Full Text] [Related]
9. Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.
Pierre-Victor D; Pinsky PF
JAMA Intern Med; 2019 Feb; 179(2):196-203. PubMed ID: 30592477
[TBL] [Abstract][Full Text] [Related]
10. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.
Tsodikov A; Gulati R; Heijnsdijk EAM; Pinsky PF; Moss SM; Qiu S; de Carvalho TM; Hugosson J; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; Feuer EJ; de Koning HJ; Mariotto AB; Etzioni R
Ann Intern Med; 2017 Oct; 167(7):449-455. PubMed ID: 28869989
[TBL] [Abstract][Full Text] [Related]
11. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
[TBL] [Abstract][Full Text] [Related]
12. Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening.
Liss MA; Chen H; Hemal S; Krane S; Kane CJ; Xu J; Kader AK
J Urol; 2015 Jan; 193(1):75-9. PubMed ID: 25066872
[TBL] [Abstract][Full Text] [Related]
13. Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial.
Pinsky PF; Parnes HL; Andriole G
BJU Int; 2014 Feb; 113(2):254-9. PubMed ID: 24053621
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Pinsky PF; Black A; Parnes HL; Grubb R; David Crawford E; Miller A; Reding D; Andriole G
Cancer Epidemiol; 2012 Dec; 36(6):e401-6. PubMed ID: 23000116
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Mortality of Lung Cancer Among Never Smokers in Relationship to Secondhand Smoking: Findings From the PLCO Trial.
Abdel-Rahman O
Clin Lung Cancer; 2020 Sep; 21(5):415-420.e2. PubMed ID: 32389507
[TBL] [Abstract][Full Text] [Related]
16. Other and All-Cause Mortality among Men Diagnosed with Prostate Cancer in the PLCO Trial.
Pierre-Victor D; Pinsky PF; Miller E; Parnes H
J Urol; 2021 May; 205(5):1372-1378. PubMed ID: 33350321
[TBL] [Abstract][Full Text] [Related]
17. Risk of prostate cancer in relatives of prostate cancer patients in Sweden: A nationwide cohort study.
Xu X; Kharazmi E; Tian Y; Mukama T; Sundquist K; Sundquist J; Brenner H; Fallah M
PLoS Med; 2021 Jun; 18(6):e1003616. PubMed ID: 34061847
[TBL] [Abstract][Full Text] [Related]
18. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
Pakarainen T; Raitanen J; Talala K; Taari K; Kujala P; Tammela TL; Auvinen A
Eur Urol; 2016 Sep; 70(3):499-505. PubMed ID: 27210461
[TBL] [Abstract][Full Text] [Related]
19. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
